Diversification and addition of capabilities key to CDMO success as end markets grow: CPHI North America panel
CDMOs need to diversify and expand their capabilities to take full advantage of strong growth in prominent end markets such as small molecule, monoclonal antibodies and cell and gene therapy, according to an industry expert on a panel at the CPHI North America hybrid event Wednesday.
Speaking at the session M&A Climate & Current Market Dynamics, David Windley, Managing Director, Jefferies Healthcare Equity Research identified these three main end markets as presenting the best opportunities for CDMOs but warned that CDMOs could not “stand still” as they continued to evolve.
“A CDMO can focus in any one of those areas, some of the biggest ones are spanning across a multiple of those areas, but I don’t think it’s really a viable strategy anymore for the long term for a service provider to be a one-trick pony in small molecules,” he told the conference. “I think you’ve got to be API and drug product, or if you’re only in drug product, you’ve got to be multi-formulation capability.”
At the other end of the spectrum, Windley said that in the cell and gene therapy sector, acquiring companies were buying up viral vector, cell therapy and plasmid DNA capabilities and combining those into a fuller offering.
When asked how larger CDMOs made the ‘build versus buy’ decision to grow via organic growth or asset acquisitions, Windley cited Catalent’s purchase of gene therapy company Paragon Bioservices in 2019 and said he believed companies’ strategy was often to buy into an end market they were not already in and then build organically from there “with perhaps the one axis of vertices that would matter would be geography.”
He said a company may decide to buy viral vector capabilities in the US but rather than build out globally from there, instead make an acquisition in Europe to “plant a viral vector flag” in the region.
According to Windley, in terms of publicly traded companies, CDMO valuations have increased 45% since the beginning of 2020 which he attributed largely to the scramble for capacity amid the COVID-19 pandemic.
“By comparison, that’s better than a lot of related sectors – CROs and the ‘pick and shovel’ suppliers to the drug development industry,” he added.
He said another indicator of how attractive the CDMO space is to investors was how much they were willing to pay to invest in them, with valuations - which had been relatively stable over a number of years - skyrocketing over the last three years.
To register for our four-week hybrid event, CPHI North America and to watch the full webinar on demand, click here.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance